The German subsidiary remains a driving force behind the British Vodafone group. However, the decline in international travel is depressing revenue.
The corona crisis slowed the business development of the telecommunications group Vodafone. In the third quarter of the financial year, which ran until the end of December, the service revenue of the German subsidiary of the British group rose slightly by one percent to 2.9 billion euros, as Vodafone announced in Dรผsseldorf on Wednesday. Of this, 1.3 billion euros went to the mobile communications division and 1.6 billion euros to the fixed network.
Growth will be held back by a decline in roaming revenues. In Corona times , fewer domestic customers used their Vodafone mobile phones on trips abroad or fewer foreign travelers in this country connected to the Vodafone network. If you consider the turnover without the roaming and wholesale division, the plus here compared to the previous year was 2.5 percent. The company did not provide any information on profit.
57 million SIM cards
With an increase of 99,000 contracts, the mobile communications division now has over 19 million contract customers, the company said. In the prepaid segment, Vodafone has 122,000 new customers. In total, Vodafone Germany now has over 30.7 million mobile customers and 57 million SIM cards in the network.
According to the company, 98,000 customers have now opted for a fast cable connection in the fixed network. Numerous customers have switched from DSL to cable. Vodafone puts the net customer growth in the entire fixed network area (cable and DSL resale) at 56,000. In total, the company has almost 11 million landline customers, 8 million of them in the cable network.
Vodafone Germany is a driving force for the British group, in other countries it went worse – group-wide Vodafone had to accept a drop in sales of 4.7 percent to 11.2 billion euros in the third quarter. If you factor out exchange rate fluctuations as well as acquisitions and sales of parts of the company, the minus was 0.3 percent on its own.